Skip to main content

and
  1. Article

    Open Access

    Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100

    Bevacizumab has broad anti-tumour activity, but substantial risk of hypertension. No reliable markers are available for predicting bevacizumab-induced hypertension.

    B P Schneider, L Li, F Shen, K D Miller, M Radovich, A O'Neill in British Journal of Cancer (2014)

  2. Article

    Open Access

    A longitudinal study of serum insulin and glucose levels in relation to colorectal cancer risk among postmenopausal women

    It is unclear whether circulating insulin or glucose levels are associated with increased risk of colorectal cancer. Few prospective studies have examined this question, and only one study had repeated measure...

    G C Kabat, M Y Kim, H D Strickler, J M Shikany, D Lane, J Luo in British Journal of Cancer (2012)

  3. No Access

    Article

    Compliance with pharmacological therapy in hypertension: can we do better, and how?

    G Thrall, G Y H Lip, D Lane in Journal of Human Hypertension (2004)

  4. No Access

    Article

    Ethnic differences in blood pressure and the prevalence of hypertension in England

    The objective of this study was to examine the prevalence of hypertension and mean blood pressures among Afro-Caribbeans and South-Asians in England compared with Caucasians. Data from the Birmingham Factory S...

    D Lane, D G Beevers, G Y H Lip in Journal of Human Hypertension (2002)

  5. No Access

    Article

    Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols

    A novel quantitative luminometric immunoassay (LIA) has been developed for the measurement of wild-type and mutant p53 protein in extracts from breast tumour tissue. The LIA was found to yield reliable estimat...

    A Borg, J Lennerstrand, M Stenmark-Askmalm, M Fernö in British Journal of Cancer (1995)

  6. No Access

    Article

    The relationship of p53 immunostaining to survival in carcinoma of the lung

    In this study 125 primary lung tumours have been immunostained with a panel of 5 anti-p53 antibodies (PAb240, PAb421, PAb1801, CM-1 and C19). These antibodies recognise different epitopes over the full extent ...

    R McLaren, I Kuzu, M Dunnill, A Harris, D Lane, KC Gatter in British Journal of Cancer (1992)

  7. No Access

    Article

    Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma

    Mouse monoclonal antibodies PAb 240 and PAb 1801 which specifically immunoprecipitate p53 protein, were used to examine 27 fresh ovarian tumours (16 serous adenocarcinomas, six endometrioid carcinomas, one muc...

    DM Eccles, L Brett, A Lessells, L Gruber, D Lane, CM Steel in British Journal of Cancer (1992)